Table 3 Baseline characteristics of the study population
Patient number | Cancer type | Systemic tumor therapy within the last 3 months | Number of selected positive-uptake segments | TBR mean | ||
|---|---|---|---|---|---|---|
FDG | DOTATATE | FDG | DOTATATE | |||
1 | Renal cell cancer | None | 8 | 6 | 2.9 | 5.6 |
2 | Follicular thyroid cancer | TSH-suppressive therapy | 7 | 2 | 2.6 | 3.3 |
3 | Pheochromocytoma, metabolically active (normetanephrines, dopamines) | None | 3 | 4 | 2.1 | 3.9 |
4 | Cancer of the gastric-esophageal junction | Xeloda, single dose 2 days prior to FDG, 6 days prior to DOTATATE PET | 0 | 0 | 1.5 | 1.8 |
5 | NET (stomach) | None | 0 | 0 | 1.7 | 2.2 |
6 | NET of unknown primary (liver metastases) | None | 6 | 3 | 2.2 | 3.4 |
7 | Carcinoid (rectum) | One cycle of Lu-177-DOTATATE 8 weeks prior to FDG, 9 weeks to DOTATATE PET | 0 | 1 | 1.7 | 2.9 |
8 | NET of unknown primary (liver metastases) | None | 5 | 2 | 2.1 | 2.9 |
9 | NET (pancreas) | One cycle of cisplatin/etoposide 1 week after FDG; 4 weeks prior to DOTATATE PET) | 2 | 1 | 1.8 | 2.4 |
10 | Carcinoid (lung), hormonally active | None | 1 | 2 | 1.7 | 2.6 |
11 | NET of unknown primary (liver metastases) | Sandostatin LAR, last injection 4 weeks prior to DOTATATE PET, then stopped | 0 | 0 | 1.5 | 2 |
12 | NET (ileum) | None | 2 | 1 | 1.7 | 2.8 |
13 | NSCLC | None | 1 | 8 | 1.8 | 5.7 |
14 | Papillary and follicular thyroid cancer | TSH-suppressive therapy | 2 | 4 | 1.9 | 3.5 |
15 | Follicular thyroid cancer | TSH-suppressive therapy | 2 | 3 | 1.9 | 3.1 |
16 | Uterine cancer | None | 0 | 0 | 1.4 | 1.3 |